Oxnard company to pursue therapeutic psychedelics – Pacific Coast Business Times

Oxnard-based Cure Pharmaceutical announced plans on March 16to use its oral film technology to deliver LSD and other psychedelic substancesto treat mental health disorders.

Cure owns the CBD company Sera Labs, and Cure has used its dissolving thin film platform, Curefilm, to deliver CBD and other cannabis compounds.

Cure has a license from the U.S. Drug EnforcementAdministration to develop treatments using substances classified under Schedule1 of the Controlled Substances Act. That includes psychedelics such as LSD; psilocybin,the psychoactive compound in hallucinogenic mushrooms; and MDMA, the pure formof the drug commonly known as ecstasy.

Some of those substances were first developed as psychiatrictreatments, and in recent years, researchers, doctors and patients have shownrenewed interest in using them in mental health treatment. Oregon legalizedpsylocibin mushrooms for therapeutic purposes last year and a number ofcompanies are pursuing FDA approval for therapeutic MDMA treatments.

In its March 16 news release, Cure cited a recentstudy published byData Bridge Market Researchthat projected theU.S. psychedelic drug market will grow from $2 billion in 2019 to $6.8 billion in2027.

Cure plans to study Curefilm as a platform for both microdoses and macrodoses of psychedelics, and expects to pursue Food and Drug Administration approval and commercialization of the products.

We are dedicated to applying our film technology to leadingcompounds in high-impact, unmet need areas, Jonathan Berlent, Cures chiefbusiness officer, said in the companys news release. Advancing thesepsychedelic product development programs helps ensure our end-goal of targetingthose patients who would have otherwise been left without an importanttreatment option. We plan to advance our programs in a strategic, thoughtful,and fiscally responsible way.

Continued here:

Oxnard company to pursue therapeutic psychedelics - Pacific Coast Business Times